127 related articles for article (PubMed ID: 2953414)
21. Phase II evaluation of menogaril in patients with advanced hypernephroma.
Long HJ; Hauge MD; Therneau TM; Buckner JC; Frytak S; Hahn RG
Invest New Drugs; 1991 Aug; 9(3):261-2. PubMed ID: 1838363
[TBL] [Abstract][Full Text] [Related]
22. Negative phase II trial of menogaril in advanced squamous, adeno- and large cell carcinoma of the lung.
Joss RA; Monfardini S; Hansen M; Dombernowsky P; Renard J; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):263-5. PubMed ID: 2833403
[No Abstract] [Full Text] [Related]
23. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
24. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
Long HJ; Schaid DJ; Schutt AJ; Ingle JN; Loprinzi CL; Edmonson JH
Am J Clin Oncol; 1988 Oct; 11(5):524-7. PubMed ID: 2972192
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
26. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Ratain MJ; Schilsky RL
Cancer Res; 1986 Sep; 46(9):4874. PubMed ID: 2942243
[No Abstract] [Full Text] [Related]
27. Menogaril: a new anthracycline agent entering clinical trials.
McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of oral menogaril administered on a once weekly schedule.
Stewart DJ; Verma S; Maroun JA; Robillard L; Earhart RH
Invest New Drugs; 1990 Feb; 8(1):43-52. PubMed ID: 2140564
[TBL] [Abstract][Full Text] [Related]
29. Anthracycline analogs: the past, present, and future.
Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
[No Abstract] [Full Text] [Related]
30. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
31. [Antitumor spectrum of TUT-7 on rat ascitic hepatoma].
Satoh H; Taguchi H; Yahagi S
Gan To Kagaku Ryoho; 1990 Feb; 17(2):287-91. PubMed ID: 2137321
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Brown TD; Goodman PJ; Fleming TR; Baker LH; Macdonald JS
Invest New Drugs; 1991 Feb; 9(1):77-8. PubMed ID: 1827433
[No Abstract] [Full Text] [Related]
33. Menogaril in the treatment of malignant mesothelioma: a phase II study.
Hudis CA; Kelsen DP
Invest New Drugs; 1992 Jul; 10(2):103-6. PubMed ID: 1386842
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assay.
Dodion P; Sanders C; Rombaut W; Rozencweig M; Kitt MM; Kenis Y; Klastersky J
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):245-9. PubMed ID: 2940092
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
Sternberg CN; Magill GB; Cheng EW; Hollander P
Am J Clin Oncol; 1988 Apr; 11(2):174-6. PubMed ID: 2965856
[TBL] [Abstract][Full Text] [Related]
36. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic.
Long HJ; Laurie JA; Wieand HS; Edmonson JH; Levitt R; Krook JE; Abu-Ghazaleh S
Cancer; 1991 Aug; 68(4):730-2. PubMed ID: 1830238
[TBL] [Abstract][Full Text] [Related]
37. The disposition of the new anthracycline antibiotic, menogarol, in mice.
Dodion P; Chang BK; Egorin MJ; Olman EA; Engisch KL; Bachur NR
Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
[TBL] [Abstract][Full Text] [Related]
39. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Vance RB; Crowley JJ; Macdonald JS; Ahmann FR
Invest New Drugs; 1991 Feb; 9(1):73-5. PubMed ID: 1851143
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
